1
Clinical Trials associated with CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)A Phase 1b Dose Escalation Study of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers in Adult Patients With Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
100 Clinical Results associated with CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)
100 Translational Medicine associated with CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)
100 Patents (Medical) associated with CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)
100 Deals associated with CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)